Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | Cell & Bioscience

Fig. 6

From: A translational perspective of the malignant hematopoietic proteoglycome

Fig. 6

Survival probabilities in AML patients presenting aberrant transcriptional levels of the different proteoglycans. Kaplan-Meier curves are based on gene expression above or below median values determined for the given proteoglycan. Datasets were retrieved from The Cancer Genome Atlas (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga and are based on: a combination of NGS-based singe-cell transcriptomics; the TCGA microarray platform (Affymetrix U133 Plus 2), including the MILE (Microarray Innovations in LEukemia) study on 2,096 patients; and BloodPool, an aggregated and integrated dataset grouping the results of multiple studies focusing on AML (see BloodSpot help and information page at https://servers.binf.ku.dk/bloodspot/)

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us